Pathophysiology of Renal DiseaseEberhard Ritz, Shaul G. Massry |
From inside the book
Results 1-3 of 75
Page 93
... treatment with prednisone was compared with no drug treatment . Prednisone was given in a daily dosage that ranged from 20 to 32 mg for the first 6 months , after which the dose was decreased gradually and was discontinued by 30 months ...
... treatment with prednisone was compared with no drug treatment . Prednisone was given in a daily dosage that ranged from 20 to 32 mg for the first 6 months , after which the dose was decreased gradually and was discontinued by 30 months ...
Page 146
... treatment produced a significant decline in stone formation rate . The actual number of stones formed during treatment was less than 26 % of the number predicted to form from chance alone . Critique of Prospective Clinical Trial The ...
... treatment produced a significant decline in stone formation rate . The actual number of stones formed during treatment was less than 26 % of the number predicted to form from chance alone . Critique of Prospective Clinical Trial The ...
Page 272
... treatment of hyper- calcemia 190 Cyclophosphamide , bladder toxicity 232 - SIADH after 233 - , treatment of membranous GN 93 -- of minimal change GN 89 -- of MPGN 97 - of RPGN 100 Cysteine / cystine , tubular transport 15 , 19 ...
... treatment of hyper- calcemia 190 Cyclophosphamide , bladder toxicity 232 - SIADH after 233 - , treatment of membranous GN 93 -- of minimal change GN 89 -- of MPGN 97 - of RPGN 100 Cysteine / cystine , tubular transport 15 , 19 ...
Contents
Renal Transport of Amino Acids Membrane Mechanisms | 14 |
Axial Heterogeneity of the Distal | 29 |
Glomerular Response | 48 |
Copyright | |
13 other sections not shown
Other editions - View all
Common terms and phrases
abnormalities acute renal failure Alport's syndrome amino acids arterial associated basement membrane blood pressure bone Brenner brush border brush border vesicles calcium oxalate calcium stone cis-platinum clin clinical collecting duct concentration cortical cyclophosphamide decrease diffuse dose drugs effects effusion Engl excretion glomerular disease glomeruli glomerulonephritis glomerulopathy granulomatosis hemodialysis hemodynamic hereditary hypercalcaemia hypercalciuria idiopathic increase infusion intercalated cells involvement Karger Kidney int lesions levels light chain mechanism mesangial metabolism mild hypertension mithramycin mmol/l mortality multiple myeloma nephritis nephron nephropathy nephrotic syndrome nephrotoxicity nifedipine normal observed parathyroid cells parathyroid hormone patients pericarditis phosphate Physiol plasma prednisone primary hyperparathyroidism progressive protein proteinuria PTH secretion pulmonary reabsorption reduction renal brush border renal disease renal function serum calcium SNGFR sodium sodium-dependent stone disease stone formation therapy thiazide thyroid hormone tion toxicity transport treatment trial tubular ultrafiltration uptake uremic urinary calcium urine values vasculitis verapamil